Cytomegalovirus (CMV) drug resistance mutation maps are updated with recent information for polymerase inhibitors, the terminase inhibitor letermovir and the UL97 kinase inhibitor maribavir. Newly mapped mutations and their phenotypes provide more detail on cross-resistance properties and suggest the need to expand the CMV gene regions covered in diagnostic testing. Next-generation deep sequencing technology offers a more sensitive, higher resolution view of emerging antiviral resistance and is recommended for use in clinical trials. Issues of standardization and diagnostic utility in comparison with traditional Sanger sequencing remain unresolved. Quality control is important for the accurate and reproducible detection of mutant viral populations in clinical specimens.

中文翻译：

---

巨细胞病毒抗病毒药物耐药的基因型诊断研究进展。

巨细胞病毒（CMV）耐药性突变图谱已更新，包含有关聚合酶抑制剂，末端酶抑制剂letermovir和UL97激酶抑制剂maribavir的最新信息。新定位的突变及其表型提供了有关交叉耐药特性的更多详细信息，并表明需要扩展诊断测试中涵盖的CMV基因区域。下一代深度测序技术可提供更灵敏，更高分辨率的新兴抗病毒抗药性视图，建议在临床试验中使用。与传统的Sanger测序相比，标准化和诊断实用性的问题仍未解决。质量控制对于准确，可重复地检测临床标本中的突变病毒种群很重要。